Moulding the shape of a metastatic cell

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 843-847

  Fais, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EZRIN; MERLIN; MOESIN; RADIXIN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; BINDING SITE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL INTERACTION; CELL PROLIFERATION; CELL SURFACE; CELL TRANSFORMATION; EDITORIAL; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; METASTASIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELL POLARITY; CELL SHAPE; CYTOSKELETAL PROTEINS; CYTOSKELETON; HUMANS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; MULTIGENE FAMILY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 77952950884     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.02.006     Document Type: Editorial

References (68)

1. SEER Cancer Statistics Review, 1975-2006 2009, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site. M.J. Horner, L.A.G. Ries, M. Krapcho, N. Neyman, R. Aminou, N. Howlader, S.F. Altekruse, E.J. Feuer, L. Huang, A. Mariotto, B.A. Miller, D.R. Lewis, M.P. Eisner, D.G. Stinchcomb, B.K. Edwards (Eds.).
2. Nguyen D.X., Bos P.D., Massagu Metastasis: from dissemination to organ-specific colonization. J Nat Rev Cancer 2009, 9:274-284.
3. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
4. Wulfkuhle J.D., Edmiston K.H., Liotta L.A., Petricoin E.F. Technology insight: pharmacoproteomics for cancer-promises of patient tailored medicine using protein microarrays. Nat Clin Pract Oncol 2006, 3:256-268.
5. Gould K.L., Bretscher A., Esch F.S., Hunter T. cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1. EMBO J 1989, 8:4133-4142.
6. Gautreau A., Louvard D., Arpin M. ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 2002, 14:104-109.
7. Andreoli C., Martin M., Le Borgne R., Reggio H., Mangeat P. Ezrin has properties to self-associate at the plasma membrane. J Cell Sci 1994, 107:2509-2521.
8. Hanzel D., Reggio H., Bretscher A., Forte J.G., Mangeat P. The secretion-stimulated 80K phosphoprotein of parietal cells is ezrin, and has properties of a membrane cytoskeletal linker in the induced apical microvilli. EMBO J 1991, 10:2363-2373.
9. Elliott B.E., Qiao H., Louvard D., Arpin M. Co-operative effect of c-Src and ezrin in deregulation of cell-cell contacts and scattering of mammary carcinoma cells. J Cell Biochem 2004, 92:16-28.
10. Endo K., Kondo S., Shackleford J., Horikawa T., Kitagawa N., Yoshizaki T., et al. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene 2009, 28:1725-1735.
11. Sarrio D., Rodriguez-Pinilla S.M., Dotor A., Calero F., Hardisson D., Palacios J. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 2006, 98:71-79.
12. Federici C., Brambilla D., Lozupone F., Matarrese P., De Milito A., Lugini L., et al. Pleiotropic function of ezrin in human metastatic melanomas. Int J Cancer 2009, 124:2804-2812.
13. Monni R., Haddaoui L., Naba A., Gallais I., Arpin M., Mayeux P., et al. Ezrin is a target for oncogenic kit mutants in murine erythroleukemia. Blood 2008, 111(6):3163-3172.
14. Zhou B., Leng J., Hu M., Zhang L., Wang Z., Liu D., Tong X., Yu B., Hu Y., Deng C., Liu Y., Zhang Q. Ezrin is a key molecule in the metastasis of MOLT4 cells induced by CCL25/CCR9. Leuk Res 2010, 34(6):769-776.
15. Khanna C., Wan X., Bose S., Cassaday R., Olomu O., Mendoza A., et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004, 10:182-186.
16. Yu Y., Khan J., Khanna C., Helman L., Meltzer P.S., Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004, 10:175-181.
17. Mäkitie T., Carpén O., Vaheri A., Kivelä T. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthal Vis Sci 2001, 42:2442-2449.
18. Akisawa N., Nishimorib I., Iwamurac T., Onishib S., Hollingsworth M.A. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 1999, 258:395-400.
19. Weng W.H., Ahlen J., Astr€om K., Lui W.O., Larsson C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005, 11:6198-6204.
20. Slater M., Cooper M., Murphy C.R. The cytoskeletal proteins alpha-actinin, ezrin, and talin are de-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium. Appl Immunohistochem Mol Morphol 2007, 15:170-174.
21. Chuan Y.C., Pang S.T., Cedazo-Minguez A., Norstedt G., Pousette A., Flores-Morales A. Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 2006, 281:29938-29948.
22. Zhang Y., Hu M.Y., Wu W.Z., Wang Z.J., Zhou K., Zha X.L., et al. The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness. J Cancer Res Clin Oncol 2006, 132:685-697.
23. Geiger K.D., Stoldt P., Schlote W., Derouiche A. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 2000, 157:1785-1793.
24. Lugini L., Lozupone F., Matarrese P., Funaro C., Luciani F., Malorni W., et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003, 83:1555-1567.
25. Lugini L., Matarrese P., Tinari A., Lozupone F., Federici C., Iessi E., et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006, 66:3629-3638.
26. Bretscher A., Edwards K., Fehon R.G. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002, 3:586-599.
27. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol Cell 2000, 92:305-316.
28. Yonemura S., Hirao M., Doi Y., Takahashi N., Kondo T., Tsukita S., et al. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 1998, 140(4):885-895.
29. Killock D.J., Parsons M., Zarrouk M., Ameer-Beg S.M., Ridley A.J., Haskard D.O., et al. In vitro and in vivo characterization of molecular interactions between calmodulin, ezrin/radixin/moesin, and l-selectin. J Biol Chem 2009, 284:8833-8845.
30. Ramoni C., Luciani F., Spadaro F., Lugini L., Lozupone F., Fais S. Differential expression and distribution of ezrin, radixin and moesin in human natural killer cells. Eur J Immunol 2002, 32:3059-3065.
31. Parlato S., Giammarioli A.M., Logozzi M., Lozupone F., Matarrese P., Luciani F., et al. CD95 (APO-1/Fas) linkare to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J 2000, 19:5123-5134.
32. Lozupone F., Lugini L., Matarrese P., Luciani F., Federici C., Iessi E., et al. Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J Biol Chem 2004, 279:9199-9207.
33. Puddu P., Fais S., Luciani F., Gherardi G., Dupuis M.L., Romagnoli G., et al. Interferon-gamma up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. Lab Invest 1999, 79:1299-1309.
34. Darmellah A., Rücker-Martin C., Feuvray D. ERM proteins mediate the effects of Na1/H1 exchanger (NHE1) activation in cardiac myocytes. Cardiovasc Res 2009, 81:294-300.
35. Hughes S.C., Fehon R.G. Understanding ERM proteins-the awesome power of genetics finally brought to bear. Curr Opin Cell Biol 2007, 19(1):51-56.
36. Patra S.K. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 2008, 1785(2):182-206.
37. Prag S., Parsons M., Keppler M.D., Ameer-Beg S.M., Barber P., Hunt J., et al. Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42. Mol Biol Cell 2007, 18(8):2935-2948.
38. Chakrabandhu K., Hérincs Z., Huault S., Dost B., Peng L., Conchonaud F., et al. Palmitoylation is required for efficient Fas cell death signaling. EMBO J 2007, 26(1):209-220.
39. Gupta N., Wollscheid B., Watts J.D., Scheer B., Aebersold R., DeFranco A.L. Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics. Nat Immunol 2006, 7(6):625-633.
40. Gajate C., Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem 2005, 280(12):11641-11647.
41. Stickney J.T., Bacon W.C., Rojas M., Ratner N., Ip W. Activation of the tumor suppressor merlin modulates its interaction with lipid rafts. Cancer Res 2004, 64(8):2717-2724.
42. Tomas E.M., Chau T.A., Madrenas J. Clustering of a lipid-raft associated pool of ERM proteins at the immunological synapse upon T cell receptor or CD28 ligation. Immunol Lett 2002, 83(2):143-147.
43. Fais S., Malorni W. Leukocyte uropod formation and membrane/cytoskeleton linkage in immune interactions. J Leukoc Biol 2003, 73(5):556-563.
44. Shaw A.S. FERMing up the synapse. Immunity 2001, 15(5):683-686.
45. McIntyre J.A., Pierce C.W., Karnovsky M.J. The formation of septate-like junctional complexes between lymphoid cells in vitro. J Immunol 1976, 116:1582-1586.
46. 2+ responses triggered in T cells by dendritic cells compared with B cells. J Exp Med 1998, 188:1473-1484.
47. Pearson M.A., Reczek D., Bretscher A., Karplus P.A. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 2000, 101:259-270.
48. Gautreau A., Louvard D., Arpin M. Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol 2000, 150(1):193-203.
49. Endo K., Kondo S., Shackleford J., Horikawa T., Kitagawa N., Yoshizaki T., et al. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene 2009, 28(14):1725-1735.
50. Tang F., Wang D., Duan C., Huang D., Wu Y., Chen Y., et al. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated ezrin phosphorylation at threonine 567. J Biol Chem 2009, 284(40):27456-27466.
51. Brambilla D., Fais S. The Janus-faced role of ezrin in " linking" cells to either normal or metastatic phenotype. Int J Cancer 2009, 125(10):2239-2245.
52. Fais S., De Milito A., Lozupone F. The role of FAS to ezrin association in FAS-mediated apoptosis. Apoptosis 2005, 10(5):941-947.
53. McClatchey A.I. Merlin and ERM proteins: unappreciated roles in cancer development?. Nat Rev Cancer 2003, 3:877-883.
54. Bai Y., Liu Y.J., Wang H., Xu Y., Stamenkovic I., Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 2007, 26:836-850.
55. Sun C.X., Robb V.A. Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci 2002, 115:3991-4000.
56. Zheng J.F., Sun L.C., Liu H., Huang Y., Li Y., He J. EBP50 exerts tumor suppressor activity by promoting cell apoptosis and retarding extracellular signal-regulated kinase activity. Amino Acids 2009, (December). [Epub ahead of print].
57. Machesky L.M. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 2008, 582(14):2102-2111.
58. Furutani Y., Matsuno H., Kawasaki M., Sasaki T., Mori K., Yoshihara Y. Interaction between telencephalin and ERM family proteins mediates dendritic filopodia formation. J Neurosci 2007, 27(33):8866-8876.
59. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009, 8(1):118.
60. Chuan Y.C., Iglesias-Gato D., Fernandez-Perez L., Cedazo-Minguez A., Pang S.T., Norstedt G., et al. Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene 2010, [Epub ahead of print].
61. Fais S., Luciani F., Logozzi M., Parlato S., Lozupone F. Linkage between cell membrane proteins and actin-based cytoskeleton: the cytoskeletal-driven cellular functions. Histol Histopathol 2000, 15(2):539-549.
62. Luciani F., Matarrese P., Giammarioli A.M., Lugini L., Lozupone F., Federici C., et al. CD95/phosphorylated ezrin association underlies HIV-1 GP120/IL-2-induced susceptibility to CD95(APO-1/Fas)-mediated apoptosis of human resting CD4 T lymphocytes. Cell Death Differ 2004, 11:574-582.
63. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
64. Bruce E., Elliott J.A.M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 2005, 7:R365-R373.
65. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., et al. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
66. Sheetz M.P., Felsenfeld D., Galbraith C.G., Choquet D. Cell migration as a five-step cycle. Biochem Soc Symp 1999, 65:233-243.
67. Estecha A., Sánchez-Martín L., Puig-Kröger A., Bartolomé R.A., Teixidó J., Samaniego R., et al. Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci 2009, 122:3492-3501.
68. Luciani F., Molinari A., Lozupone F., Calcabrini A., Lugini L., Stringaro A., et al. P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood 2002, 99:641-648.